SCHEMBL10293443

SCHEMBL10293443

CC(C)c1coc2cnccc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.42
IDO1 P14902 4/20 0.35
RPS6KA3 P51812 1/20 0.34
LMNA P02545 1/20 0.34
GSK3B P49841 2/20 0.33
KDM4C Q9H3R0 1/20 0.33
TDO2 P48775 4/20 0.32
PIM2 Q9P1W9 1/20 0.32
NFATC1 O95644 1/20 0.32
DYRK1A Q13627 1/20 0.32
ROCK2 O75116 1/20 0.32
ALOX5 P09917 1/20 0.31
CYP19A1 P11511 3/20 0.31
CYP17A1 P05093 1/20 0.30
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30
PTPN1 P18031 1/20 0.30
LATS1 O95835 1/20 0.30
LATS2 Q9NRM7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293453 0.89 RPS6KA3 (0.34) MTNR1AIDO1RPS6KA3LMNAGSK3B
SCHEMBL8341650 0.75 MTNR1A (0.45) MTNR1AIDO1GSK3BTDO2CYP17A1
SCHEMBL904863 0.74 MAOB (0.41) CYP19A1PTPN1
SCHEMBL19759424 0.72 HTR2A (0.37)
SCHEMBL246967 0.71 MTNR1A (0.42) MTNR1AIDO1LMNATDO2
SCHEMBL3610557 0.71 MTNR1A (0.45) MTNR1AIDO1RPS6KA3LMNAGSK3B
SCHEMBL12032784 0.70 RPS6KA3 (0.39) IDO1RPS6KA3LMNAGSK3BTDO2
SCHEMBL27010999 0.69
SCHEMBL21237825 0.69 IDO1 (0.43) IDO1LMNATDO2ROCK2
SCHEMBL21237915 0.68 IDO1 (0.42) IDO1LMNATDO2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 US disclosed
US-20230365526-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2023-11-16 US disclosed
US-20230365566-A1 HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2023-11-16 US disclosed
EP-3870582-B1 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2023-07-19 EP disclosed
US-20230167093-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-06-01 US disclosed
US-20230159496-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2023-05-25 US disclosed
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230140983-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2023-05-11 US disclosed
US-20230148184-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2023-05-11 US disclosed
US-20120172369-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MERCK SHARP & DOHME CORP. 2012-07-05 US disclosed
US-20120172369-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MERCK SHARP & DOHME CORP. 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365566-A1 HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING RBM17, HNRNPA1, HNRNPAB MTNR1A 2771/4885IDO1 4647/4885RPS6KA3 679/4885
US-20230159496-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 MTNR1A 2839/4885IDO1 4840/4885RPS6KA3 788/4885
US-20120172369-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT MTNR1A 2212/4885IDO1 2506/4885RPS6KA3 1831/4885
US-20230167093-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 MTNR1A 2839/4885IDO1 4840/4885RPS6KA3 788/4885
US-20230148184-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 MTNR1A 2839/4885IDO1 4840/4885RPS6KA3 788/4885
US-20230365526-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING SNRPA, RBM17, SNRPB2 MTNR1A 2508/4885IDO1 4001/4885RPS6KA3 996/4885
US-20230142338-A1 THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN3, NSUN2 MTNR1A 2125/4885IDO1 4538/4885RPS6KA3 936/4885
US-20230140983-A1 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING SNRPA, RBM17, SNRPB2 MTNR1A 2508/4885IDO1 4001/4885RPS6KA3 996/4885
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T HNRNPAB, HNRNPC, HNRNPA1 MTNR1A 3429/4885IDO1 1072/4885RPS6KA3 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.